Transcriptome Signature Post Reovirus Treatment In KRAS Mutated Colorectal Cancer

ABSTRACT: Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45-50% of CRC patients possess KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patient samples possessing KRAS mutated metastatic CRC. This is the raw data from the peripheral mononuclear cell (PBMC) samples at 4 timepoints (pre treatment, 48 hours, day 8, and day 15).

ORGANISM(S): Homo sapiens

PROVIDER: GSE173636 | GEO | 2021/05/01

REPOSITORIES: GEO